A|B|C|D|E|F|G|H|I|J|K|L|M|N|O|P|Q|R|S|T|U|V|W|X|Y|Z|ALL

  检 索： 期刊名称 ISSN         高级检索

期刊名称：EXPERT OPINION ON THERAPEUTIC TARGETS ISSN： 1472-8222 出版频率： Monthly 出版社： TAYLOR & FRANCIS LTD, 2-4 PARK SQUARE, MILTON PARK, ABINGDON, England, OXON, OX14 4RN   出版社网址： http://informahealthcare.com/ 期刊网址： http://informahealthcare.com/loi/ett 影响因子： 6.902 主题范畴： PHARMACOLOGY & PHARMACY 期刊简介(About the journal)    投稿须知(Instructions to Authors)    编辑部信息(Editorial Board)    About the journal Expert Opinion on Therapeutic Targets (ISSN 1472-8222) is the premier journal dedicated to in-depth reports and reviews of the latest developments in the field of drug target discovery and validation. Expert Opinion on Therapeutic Targets is a peer-reviewed journal providing evaluated and expert reviews of recent research identifying novel molecular drug targets. The journal provides an essential link between basic research on biological pathways and interactions, and the development of the drugs of tomorrow. It is distinguished from other publications by its high-quality authorship and expertly drafted articles, which are structured to incorporate the author's own expertise on the subject. The audience consists of scientists, managers and decision makers in the pharmaceutical industry, and others closely involved in R&D. Subscribers include most of the major pharmaceutical companies in the USA, Europe and Japan, as well as many biotechnology companies. Each volume of the journal contains a selection of commissioned review articles focusing on the following therapeutic areas: Anti-infective Anti-inflammatory Cardiovascular & Renal Central & Peripheral Nervous Systems Oncologic, Endocrine & Metabolic Instructions to Authors The Commissioning Editor, under the advice of the Editorial Advisory Board, solicits articles published by Ashley Publications. However, suggestions for article topics (and potential authors) are welcome, subject to final approval by the Editors and Editorial Advisory Board. If you are interested in preparing an article, please contact the Commissioning Editor of the relevant journal with your proposal and an outline. The following guidelines are provided to assist authors in the preparation of their manuscript. Expert Opinion on Biological Therapy Editorial Guidelines Review Guidelines Meeting Highlight Guidelines Drug Evaluation Guidelines Expert Opinion on Drug Delivery Editorial Guidelines Review Guidelines Meeting Highlight Guidelines Technology Evaluations Guidelines Expert Opinion on Drug Metabolism & Toxicology Review Guidelines Editorial Guidelines Drug Evaluation Guidelines Expert Opinion on Drug Safety Editorial Guidelines Review Guidelines Meeting Highlight Guidelines Correspondence Guidelines Expert Opinion on Emerging Drugs Editorial Guidelines Review Guidelines Meeting Highlights Guidelines Expert Opinion on Investigational Drugs Editorial Guidelines Review Guidelines Clinical Trials Report Guidelines Drug Evaluation Guidelines Expert Opinion on Pharmacotherapy Editorial Guidelines Review Guidelines Meeting Highlights Drug Evaluation Guidelines Key Paper Evaluation Expert Opinion on Therapeutic Patents Editorial Guidelines Review Guidelines Meeting Highlights Patent Analysis Guidelines Patent Evaluation Guidelines Expert Opinion on Therapeutic Targets Review Guidelines Meeting Highlights Guidelines References Expert Opinion EndNote Style Submission Please submit manuscripts in Microsoft Word 2000 format via e-mail to the Commissioning Editor of the relevant journal. Figures should be submitted as Microsoft PowerPoint, Adobe Illustrator or Photoshop (*.eps). Graphs and charts can also be submitted as Microsoft Excel. Copyright As the author of your manuscript, you are responsible for obtaining permissions to use material owned by others. Since the permission-seeking process can be time-consuming, it is wise to request permission as soon as possible. A template permission letter is available upon request by contacting the Commissioning Editor of the relevant journal. Please send us photocopies of letters or forms granting you permission for the use of copyrighted material so that we can see that any special requirements with regard to wording and placement of credits are fulfilled. Please keep the originals for your files. Editorial Board Editorial Staff Commissioning Editor: Emma Quigley Production Editor: Jonathan Collard Anti-infectives Bischofberger N: Gilead Sciences, USA Keith D: Cubist Pharmaceuticals, USA McKenzie G: Lorantis, UK Meinnel T: CNRS, USA Palfreyman M: Novace Corp., USA Preobrazhenskaya M: Gause Institute of New Antibiotics, Russia Selitrennikoff C: MycoTox, USA Smith P: GlaxoSmithKline, UK Sofia M: Transcell Technologies, Inc., USA Vovis G: Genaissance Pharmaceuticals, USA Anti-inflammatory Kingsmore S: National Center for Genome Resources, USA Rainsford K: Sheffield Hallam University, UK Solari R: Medical Research Council, UK Tilg H: University Hospital Innsbruck, Austria Zollner TM: Schering, Germany Cardiovascular & Renal Egido J: Universidad Autonoma, Madrid, Spain Morishita R: Osaka University, Japan Saxena U: Reddy US Therapeutics, USA Tedgui A: Inserm U541 - Hopital Lariboisiere, France Central & Peripheral Nervous Systems Begley D: KCL, UK Gurwitz D: Tel Aviv Univ., Israel Rubinow DR: NIH, USA Tedford C: Gliatech, USA Sher E: Eli Lilly, UK Oncologic, Endocrine & Metabolic Bennett CF: ISIS Pharmaceuticals, USA Blagosklonny M: New York Medical College, USA Caron PR: Vertex Pharmaceuticals, USA Debouck C: GlaxoSmithKline, USA Garcia-Echeverria C: Novartis, Switzerland McCubrey JA: East Carolina University, USA O'Connell J: University Hospital, Cork, Ireland Reed J: Burnham Inst., USA Robson S: Harvard University, USA Sawyer T: ARIAD Pharmaceuticals, USA Spurr NK: GlaxoSmithKline, USA